• Aligos Therapeutics announced five abstracts accepted for AASLD’s The Liver Meeting 2026 in Denver on Nov. 5-9.
• Results have not been presented yet; the company scheduled poster presentations for Nov. 7-8.
• Data highlight pevifoscorvir sodium in chronic hepatitis B, pointing to immune effects and signs of sustained viral suppression over longer treatment.
• Separate updates cover ALG-170675 for hepatitis B, supported by preclinical efficacy and safety signals.
• A preclinical program, ALG-215007, showed antiviral activity against hepatitis delta virus in laboratory studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610051605PRIMZONEFULLFEED9838801) on October 05, 2026, and is solely responsible for the information contained therein.